| Catalog No. |
TD-VK421026 |
| Species reactivity |
HRSV-A |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG1, kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P03420 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
MEDI-8897,MEDI8897,CAS:1989556-22-0 |
| Background |
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |